The Catalan company Inbiomotion secures 2,2 million euros of funding


El Periódico”, “La Vanguardia”, “Ara”, and other media, report on the new round of funding received by the biotech company Inbiomotion, a spin-off of IRB Barcelona specialized in predicting the risk of bone metastases in breast cancer patients. The company was founded in 2010 by Roger Gomis, ICREA researcher and group leader of Growth control and cancer metastasis at IRB Barcelona.

Led by "La Caixa", the round of funding closed with a concession of 2.2 million euros. Ysios Capital and Fundación Vila Casas also participated in this operation.